Featured News

May 3rd, 2021

Shear Insights: Peer-Reviewed Journal Publishes the Discovery of HemoShear’s HST5040 Small Molecule in Clinical Development for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Read More »
April 21st, 2021

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Read More »
March 31st, 2021

Molecular Genetics and Metabolism Publishes Primary Pharmacology Data Supporting HemoShear’s HST5040 as a Potential Treatment for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

Read More »
February 10th, 2021

HemoShear Therapeutics Raises $40 Million in Series A Financing to Advance Rare Disease Portfolio

Read More »
December 16th, 2020

HemoShear Therapeutics’ HST5040 Receives U.S. Orphan Drug Designations for Treatment of Methylmalonic Acidemia and Propionic Acidemia

Read More »
September 29th, 2020

Shear Insights: Mavis Waller Appointed to Vice President, Clinical Operations as HemoShear Readies for Clinical Trials

Read More »
July 9th, 2020

HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout

Read More »
June 24th, 2020

HemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040 for the Treatment of Methylmalonic Acidemia and Propionic Acidemia

Read More »
June 4th, 2020

Shear Insights: Journal Publishes HemoShear Models for Rare Metabolic Diseases

Read More »
November 14th, 2019

Shear Insights: HemoShear Therapeutics Engages with European Metabolic Disease Consortium

Read More »
September 25th, 2019

HemoShear Therapeutics Appoints Brian A. Johns, PhD, Chief Scientific Officer

Read More »
September 20th, 2019

Prestigious Journal Publishes HemoShear Research on Gene Expression and Liver Disease

Read More »
View More +

Contact

info@hemoshear.com

HemoShear Therapeutics, Inc.
501 Locust Avenue
Suite 301
Charlottesville, Virginia 22902